Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Removed Hepatocellular carcinoma from the Conditions list and removed the Genetic and Rare Diseases Information Center resource under Resources.
    Difference
    0.2%
    Check dated 2026-03-28T23:40:08.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Added the MeSH term 'Hepatocellular carcinoma' and a link to the Genetic and Rare Diseases Information Center; updated page revision from v3.4.3 to v3.5.0.
    Difference
    0.2%
    Check dated 2026-03-21T15:41:36.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    Updated site revision from v3.4.2 to v3.4.3. No visible changes to the study details page.
    Difference
    0.1%
    Check dated 2026-03-06T21:06:21.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Updated the site revision from v3.4.1 to v3.4.2; no user-facing content or functionality appears to be affected.
    Difference
    0.1%
    Check dated 2026-02-13T13:29:05.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1, which appears to be a minor backend/system update with no visible changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-06T09:17:58.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    Glossary visibility controls were added (Show glossary, Hide glossary) and footer metadata was updated to Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-01-22T18:29:14.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.